IP Library Granted Patent US 10,251,908
Granted Patent B2
US 10,251,908 · App. 14/738,417 · Granted Apr 9, 2019

Vitamin B

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,251,908
App. No.
14/738,417
Granted
Apr 9, 2019
Kind
B2
Abstract

The present invention relates generally to vitamin B 12 nasal spray compositions and methods of using the same in the treatment of vitamin B 12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.

Claims (23)

1. A method for maintaining vitamin B12 blood serum levels in a subject, the method comprising intranasally administering to the subject in need thereof a composition such that a dose of from about 5 μg to about 45 μg of cyanocobalamin is administered, wherein the composition comprises an aqueous solution containing about 1% w/w cyanocobalamin, a pharmaceutically acceptable buffer, a humectant, and a preservative, and wherein:

the buffer comprises a citrate buffer;

the humectant comprises glycerin;

the preservative comprises benzalkonium chloride;

the composition has a pH of about 4 to about 6.5, and

the composition is provided in a container equipped with a pump adapted to deliver the composition into a patient's nostril.

2. The method according to claim 1 , comprising administering the dose of cyanocobalamin in a plurality of metered sprays of the composition.

3. The method according to claim 1 , comprising administering the dose of cyanocobalamin in a single metered spray of the composition.

4. The method of claim 1 , wherein the composition is administered to provide a weekly dosage of from about 100 μg to about 1000 μg of cyanocobalamin.

5. The method of claim 1 , wherein the composition is administered to provide a weekly dosage of from about 100 μg to about 800 μg of cyanocobalamin.

6. The method of claim 1 , wherein the composition is administered to provide a weekly dosage of from about 100 μg to about 500 μg of cyanocobalamin.

7. The method of claim 1 , wherein the dose is administered once daily.

8. A method for maintaining normal hematologic status in a pernicious anemia patient following intramuscular vitamin B12 injection therapy, said method comprising intranasally administering to the patient a composition such that a dose of from about 5 μg to about 45 μg of cyanocobalamin is administered, wherein the composition comprises an aqueous solution containing about 1% w/w cyanocobalamin, a pharmaceutically acceptable buffer, a humectant, and a preservative, and wherein:

the buffer comprises a citrate buffer;

the humectant comprises glycerin;

the preservative comprises benzalkonium chloride;

the composition has a pH of about 4 to about 6.5, and

the composition is provided in a container equipped with a pump adapted to deliver the composition into a patient's nostril.

9. The method according to claim 8 , comprising administering the dose of cyanocobalamin in a plurality of metered sprays of the composition.

10. The method according to claim 8 , comprising administering the dose of cyanocobalamin in a single metered spray of the composition.

11. The method of claim 8 , wherein the composition is administered to provide a weekly dosage of from about 100 μg to about 1000 μg of cyanocobalamin.

12. The method of claim 8 , wherein the composition is administered to provide a weekly dosage of from about 100 μg to about 800 μg of cyanocobalamin.

13. The method of claim 8 , wherein the composition is administered to provide a weekly dosage of from about 100 μg to about 500 μg of cyanocobalamin.

Assignments (12)
SECURITY INTEREST Recorded Jul 22, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068469/0001 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA
Reel/Frame 068461/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2024
From: ENDO USA, INC.
To: ENDO OPERATIONS LIMITED
Reel/Frame 067245/0492 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: ENDO PHARMACEUTICALS INC.
To: ENDO USA, INC.
Reel/Frame 067203/0398 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: PAR PHARMACEUTICAL, INC.; ENDO PAR INNOVATION COMPANY, LLC
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 043118/0747 →
SECURITY INTEREST Recorded Jun 8, 2017
From: PAR PHARMACEUTICAL, INC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0216 →
CHANGE OF ADDRESS Recorded Apr 1, 2016
From: PAR PHARMACEUTICAL, INC.
To: PAR PHARMACEUTICAL, INC.
Reel/Frame 038324/0841 →
CHANGE OF NAME Recorded Jun 17, 2015
From: FLEMING & COMPANY, PHARMACEUTICALS
To: PAR PHARMACEUTICAL, INC.
Reel/Frame 035854/0230 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2015
From: FELLER, THEODORE H.; SUTTERER, ANGELA; FLEMING, THOMAS E.
To: FLEMING & COMPANY, PHARMACEUTICALS
Reel/Frame 035941/0983 →